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Abstract
We have previously identified an androgen-responsive
gene in rat prostate that shares homology with the aci-
reductone dioxygenase (ARD/ARDV) family of metal-
binding enzymes involved in methionine salvage. We
found that the gene, aci-reductone dioxygenase 1 (ADI1),
was downregulated in prostate cancer cells, whereas
enforced expression of rat Adi1 in these cells caused
apoptosis. Here we report the characterization of human
ADI1 in prostate cancer. Androgens induced ADI1 ex-
pression in human prostate cancer LNCaP cells, which
was not blocked by cycloheximide, indicating that ADI1
is a primary androgen-responsive gene. In human be-
nign prostatic hyperplasia specimens, epithelial cells
expressed ADI1. Immunohistochemistry of prostate
tumor tissue microarrays showed that benign regions
expressed more ADI1 than tumors, suggesting a sup-
pressive role for ADI1 in prostate cancer. Bacterial ly-
sates containing recombinant ADI1 produced a five-fold
increase in aci-reductone decay over controls, demon-
strating that ADI1 has ARD activity. We generated point
mutations at key residues in the metal-binding site of
ADI1 to disrupt ARD function, and we found that these
mutations did not affect intracellular localization, apop-
tosis, or colony formation suppression in human pros-
tate cancer cells. Collectively, these observations argue
that ADI1 may check prostate cancer progression
through apoptosis and that this activity does not require
metal binding.
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Introduction
Prostate cancer remains the most frequently diagnosed
cancer and second leading cause of cancer-related deaths
in American men [1]. As androgens are intimately asso-
ciated with disease progression, elucidating the roles and
mechanisms of androgen action in prostate cancer is rele-
vant to the prevention and treatment of the disease [2–4].
Androgen action is mediated through the androgen receptor, a
ligand-dependent transcription factor that regulates the ex-
pression of androgen-responsive genes [5,6]. Thus, the iden-
tification and characterization of androgen-responsive genes in
the prostate will likely provide insights into the mechanism by
which androgens influence prostate cancer progression.
We have previously identified and characterized a rat
androgen-responsive gene that encodes a 179–amino acid
polypeptide with high homology to the ARD/ARDV family [7]. We
initially designated this gene as aci-reductone dioxygenase-
like protein-1 (ALP-1), but to correspond with the official
gene nomenclature, we have since renamed it aci-reductone
dioxygenase-1. The ARD/ARDV family, first discovered in
Klebsiella pneumoniae, consists of evolutionarily conserved
enzymes from the methionine salvage pathway, which recycles
the g-thiomethyl of methylthioadenosine to methionine [7–13].
Methylthioadenosine is both a product and a potent down-
regulator of polyamine biosynthesis [14]. ARD catalyzes the
penultimate step in the pathway, the oxidative decomposition of
1,2-dihydoxy-3-keto-5-(thiomethyl)pent-1-ene (aci-reductone)
to formate and 2-keto-4-(thiomethyl)butyrate, the keto-acid
precursor of methionine. This activity requires the enzyme to
bind metal, and the products formed depend on which metal is
bound. In bacterial enzymes, the association of ARD with Ni2+
results in ARD-mediated production of carbon monoxide, for-
mate, and methylthiopropionate, whereas association with
Fe2+ results in ARDV-mediated production of formate and the
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keto-acid precursor to methionine [8,9,15]. Nuclear magnetic
resonance–derived solution structures of the Klebsiella en-
zyme and the crystallographic structure of the ARD ortholog
from Mus musculus have identified key histidine and gluta-
mic acid residues within a conserved domain responsible for
metal binding [9,13,16].
Evidence suggests a possible role for aci-reductone dioxy-
genase 1 (ADI1) in prostate cancer. We observed a down-
regulation of ADI1 in rat and human prostate cancer cell
lines. Moreover, enforced expression of rat Adi1 in these
prostate cancer cells induced apoptosis, suggesting that
Adi1 may have an inhibitory role in prostate cancer [7].
Through a yeast two-hybrid screen, Uekita et al. independently
identified humanADI1. Using the cytoplasmic tail of membrane
type I matrix metalloproteinase (MT1-MMP) as bait yielded
MT1-MMP cytoplasmic tail–binding protein-1 (MTCBP-1) as
a potential binding partner [17]. Sequence comparison char-
acterized MTCBP-1 as an ortholog of rat Adi1. Transient
expression of human ADI1 in fibroblast cell lines inhibited
MT1-MMP–mediated migration and Matrigel invasion [17].
Similar to prostate cancer cells, cultured gastric carcinoma
cells and fibrosarcoma cells also have downregulated ADI1
[7,17], consistent with an inhibitory role in tumor progression.
However, it remains unknown whether ADI1 expression
also undergoes downregulation in human cancer specimens.
Recent work has demonstrated the ability of human ADI1
to function in methionine metabolism in yeast. Saccharomy-
ces cerevisiae can grow under sulfur-depleted conditions,
using the methionine salvage pathway to regenerate methi-
onine. Disruption of the yeast homolog of ARD YMR009w
blocks this growth, which ADI1 expression restores. This in-
dicates that ADI1 is functionally conserved and can act as
an ARD in yeast [18]. However, biochemical evidence for
human ADI1 as an ARD enzyme is still lacking. In addition, it
is unknownwhether the enzymatic activity of ADI1 is required
for its observed proapoptic activity in prostate cancer cells.
In this study, we further explore the expression and en-
zymatic activity of ADI1 in prostate cancer. We show the
androgen regulation of human ADI1 expression in prostate
cancer cells and the downregulation of its expression in
human prostate cancer specimens, further supporting a role
for ADI1 in prostate cancer progression. We also provide
biochemical evidence that ADI1 can truly act as an ARD
enzyme. Surprisingly, point mutations that disrupt the pre-
dicted metal-binding site essential for ADI1 enzymatic activ-
ity did not affect the ability of the protein to induce apoptosis
and to suppress colony formation in prostate cancer cells,
suggesting that these activities may be independent of ARD
enzymatic activity.
Materials and Methods
Cloning of Human ADI1 cDNA and Construction
of ADI1 Mutants
A full-length cDNA clone encoding human ADI1 was
isolated from a EZAP phage cDNA library and was prepared
using LNCaP mRNA (Stratagene, La Jolla, CA). Rat ADI1
cDNA was used as a probe using low-stringency conditions.
In vivo excision of the EZAP phage yielded a pBluescript
II SK plasmid (Stratagene, La Jolla, CA), with human ADI1
cDNA inserted at the EcoRI and XhoI sites between T3 and
T7 promoters. Nested deletion mutants were generated
using the Erase-a-Base kit (Promega, Madison, WI) and
then sequenced using the Alpha Express automated se-
quencing machine (Amersham Pharmacia, Piscataway, NJ).
Both strands of cDNA were sequenced completely. Se-
quence assembly and analysis were carried out using the
DNASIS program (Hitachi Software, San Francisco, CA).
The Quickchange Site-Directed Mutagenesis kit (Strata-
gene) was used to make ADI1 mutants: H1 (His88Ala), H2
(His90Ala), H3 (His133Ala), E1 (Glu94Ala), H1H2 (His88Ala
and His90Ala), H1H2E1 (His88Ala, His90Ala, and Glu94Ala),
and H1H2H3E1 (His88Ala, His90Ala, His133Ala, and
Glu94Ala). In each case, histidine or glutamic acid was con-
verted to an alanine, and all mutants were sequenced to con-
firm the mutation.
In Situ Hybridization
Sense and antisense ADI1 RNA probes labeled with
digoxygenin (DIG) were used for in situ hybridization studies.
A full-length ADI1 cDNA inserted at the multiple cloning site
of the pBluescript II SK plasmid was used in template prep-
aration. Linearized proteinase K–treated plasmid DNA tem-
plates were prepared as described previously [19,20], and
the synthesis of sense and antisense RNA probes was car-
ried out by in vitro transcription using a DIG RNA labeling mix
of nucleotides (Roche Molecular Biochemicals, Indianapolis,
IN) with either T3 or T7 RNA polymerase (Promega). In situ
hybridization was carried out according to the method of
Furlow et al. [20] with minor modifications, as described in
Cyriac et al. [19].
Tissue Array and Immunohistochemistry
Human radical prostatectomy specimens were obtained
with consent and constructed into tissue microarrays (North-
western University Urology Department and Pathology Core
Facility). Each tissue core was evaluated and given a diag-
nosis by a genitourinary pathologist. Immunohistochemistry
staining of tissue cores using purified antibodies (anti-ADI1
polyclonal antibody) [7] was performed at the Northwestern
Pathology Core Facility. Two observers independently iso-
lated the area of pathological diagnosis within the tissue core
and scored the intensity of immunostaining using subjective
Grizzle scores (1–4, with 4 = the highest level of intensity)
[21]. If the scoring discrepancy between the two observers
was z 1.5, the tissue core was discarded from analysis. An
average Grizzle score for each type of prostatic histology
was then determined.
Cell Culture
LNCaP and PC3 prostate cancer cells were obtained
from the American Type Culture Collection (Manassas, VA)
and maintained in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS), 1% glutamine, and 1% penicillin–
streptomycin at 37jC in a humidified atmosphere containing
644 Human ADI1 in Prostate Cancer Oram et al.
Neoplasia . Vol. 9, No. 8, 2007
5% CO2. LNCaP cells were cultured in phenol red–free
RPMI 1640 plus 10% charcoal-stripped FBS (cFBS) for 2 days
before treatment with a synthetic androgen, Mibolerone (Mib;
NEN Life Science Products, Boston, MA). For time-course
studies, cells were treated with 1 nM Mib for indicated hours.
To determine whether ADI1 is a direct androgen-responsive
gene, LNCaP cells were treated with cycloheximide (CHX;
Sigma, St. Louis, MO) at 10 mg/ml for 2 hours before treatment
with 1 nM Mib for 24 hours.
Western Blot Analysis
Cells were collected at indicated time points and lysed in
a 1% sodium dodecyl sulfate (SDS) lysis buffer. Protein con-
centrations of cell lysates were determined using a Bio-Rad
DC protein assay kit (Bio-Rad, Hercules, CA) and 30 mg of
proteins loaded per well. Proteins were separated by SDS
polyacrylamide gel electrophoresis (PAGE) and transferred
to nitrocellulose, and Western blot analysis was performed
as previously described [7]. The ADI1 polyclonal antibody,
generated using a human ADI1 peptide sequence and affin-
ity purification, has been previously shown to react strongly
against human ADI1 [7]. Blots were incubated with ADI1 anti-
bodies. After incubation with secondary antibodies linked to
horseradish peroxidase, proteins were visualized by enhanced
chemiluminescence. b-Actin was probed using antibodies
obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Total RNA Isolation and Northern Blot Analysis
Total RNAwas isolated fromLNCaPcells using theRNeasy
mini kit (Qiagen, Germantown, MD). Total RNA (10 mg) was
electrophoresed through a 1% agarose formaldehyde gel,
transferred to a nylon membrane, and then cross-linked to
the membrane by UV irradiation. The transferred membrane
and the premade multiple tissue Northern blot analyses pur-
chased from Clontech (Palo Alto, CA) were hybridized over-
night with a human ADI1 cDNA probe labeled by random
priming with a-[32P]dCTP at 42jC in a solution containing 5
sodium chloride sodium phosphate EDTA, 2 Denhardt’s
solution, 0.1% SDS, 100 mg/ml denatured salmon sperm
DNA, and 50% formamide. The membrane was then washed
at room temperature with 1 saline sodium citrate (SSC) and
0.1% SDS for 20minutes followed by three 20-minute washes
at 65jC with 0.2 SSC and 0.1% SDS, and then exposed to
X-ray film with an intensifying screen at 80jC.
Subcellular Localization and Apoptosis Assay
The coding region for human wild-type and mutant ADI1
was cloned into the pEGFP-C1 vector (Clontech) at the
EcoRI and KpnI sites within the multiple cloning site (MCS),
creating green fluorescent protein (GFP) fusion proteins at
the N-terminus. Constructs were confirmed by restriction di-
gestion and sequence verification as correct. Plasmid DNA
for transient transfection were prepared using double-CsCl
gradient banding.
Transient transfection for cell death genes has been de-
scribed in Miura and Yuan [22]. Ten thousand PC3 cells were
plated per well on six-well plates (for quantitation of apopto-
sis) or on coverslips (for subcellular localization), and trans-
fections were carried out 24 hours later. pEGFP-C1, pEGFP-
C1 + ADI1, or vectors were transfected into PC3 cells by
FuGene transfection reagent (Roche, Basel, Switzerland).
Transfections were carried out using a 6:1 transfection re-
agent/DNA ratio (1 mg/well DNA). At 24 hours posttransfec-
tion, cover slips were washed in phosphate-buffered saline
(PBS), fixed in 3.7% formaldehyde solution for 10 minutes,
washed thrice in PBS, transferred, and then sealed to
microscope slides using Vectashield (Vector Laboratories,
Burlingame, CA). The slides were viewed and pictures were
taken on a Laser Scanning Confocal Microscope (LSM510;
Zeiss, Jena, Germany) at the Cell Imaging Facility of North-
western University. Quantitation of apoptosis was performed
as previously described [7].
Colony Formation Assay
LNCaP cells, at 80% confluence in six-well plates, were
transfected with GFP-tagged ADI1, GFP-tagged ADI1 mu-
tants, or empty vector pEGFP-C1 using Lipofectamine2000
(Invitrogen, Carlsbad, CA) at the same ratio used for PC3
cells. After 24 hours, all cells in each well were reseeded onto
10-cm tissue culture dishes with a medium containing G418
(500 mg/ml; Invitrogen) and then cultured for 3 weeks to allow
colonies to develop. The medium was replaced weekly. All
colonies larger than 1 mm in diameter were counted, and the
number of GFP-positive colonies was noted. Each colony for-
mation assay was carried out in triplicate and repeated at
least thrice. All data obtained from colony formation assays
were analyzed using GraphPad Prism (GraphPad Software,
Inc., San Diego, CA). The statistical significance of differ-
ences in data was calculated using Tukey’s Multiple Com-
parison Test.
ADI1 Protein Expression and Enzyme Activity Assay
Escherichia coli BL21 (DE3) cells were transformed with
empty pET28a vector or pET28a containing the coding se-
quence of the human ADI1 gene (pET-ADI1). Cultures were
grown in Luria-Bertani broth with kanamycin (10 mg/ml) up
to an OD600 of 0.6, at which point protein expression was
induced with 0.5 mM isopropylthiogalactoside (IPTG). In-
duced cultures were grown for 3.5 hours and then resus-
pended in 30mMpotassiumphosphate buffer, pH7.5 (1:4,wt/
vol). Cells were lysed by sonication, and insoluble fraction
removed by centrifugation. The concentration of protein in the
soluble fraction was determined with Bradford reagent (Bio-
Rad). Lysates were separated on 15% SDS polyacrylamide
gels and stained by Coomassie blue or transferred to nitro-
cellulose membrane for Western blot analysis, using anti-
ADI1 antibodies as described previously [7].
ADI1 protein activity was tested against the substrate
analog, 3-keto-1,2-dihydroxyhex-1-ene (aci-reductone). Aci-
reductone was prepared by anaerobically incubating 60 mM
2,3-diketo-1-phosphohexane with purified recombinant E1
enolase/phosphatase in 20 mM HEPES (pH 7.5) and 5 mM
MgCl2 with 10 mg/ml catalase [23]. Aci-reductone production
was monitored by the increase in absorbance at 305 nm
(E305 nm = 20,000 M
1 cm1) on a Hewlett Packard 8452
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photodiode array spectrophotometer (Hewlett Packard Co.,
Houston, TX). When no further increase in aci-reductone
levels was observed, soluble cell lysate was added aerobi-
cally, and the decay of the substrate was monitored by fol-
lowing the changes in absorbance at 305 nm. Progress curves
appeared to have two phases and were best described with a
double exponential decay equation (SigmaPlot; Systat Soft-
ware, Inc., San Jose, CA). The rate constant for the fast phase
was used to calculate the specific activity of cellular extract.
Results
Structure and Sequence of the Human ADI1 Gene
A National Center for Biotechnology Information data-
base search revealed that the human ADI1 gene is located
on the short arm of chromosome 2 at 2p25.3. The human
ADI1 gene consists of four exons that encode a predicted
protein of 179 amino acids (Figure 1). This protein displays
high homology to the ARD/ARDV domain (pfam entry 03079)
initially described in bacterial protein [9]; ADI1 has a double-
stranded b-helix domain that both characterizes members of
the cupin superfamily [24] and contains the ARD active site
[9]. Indeed, ADI1 possesses the three histidines (His88,
His90, and His133) and the glutamic acid (Glu94) required
for members of the ARD/ARDV family to bind metal (Figure 1)
[8,9,15,16,25].
ADI1 mRNA Is Expressed in a Variety of Human Tissues
The rat prostate expresses high levels of ADI1 [7]. To test
whether human prostate also expresses high levels of ADI1
mRNA, we probed two commercially available human tissue
Northern blot membranes using ADI1 cDNA as a probe. As
expected, the human prostate expressed abundant levels
of ADI1 mRNA at the predicted size of 1.6 kb (Figure 2). In
addition, multiple other tissues also expressed ADI1 mRNA,
with the liver, kidney, thyroid, and skeletal muscle having
the highest levels, and with leukocytes and the brain having
barely detectable levels.
ADI1 Is Expressed in Prostatic Epithelial Cells
The prostate consists of mainly two cell types: epithelial
and stromal. In situ hybridization experiments were per-
formed on human benign prostatic hyperplasia (BPH) tissues
to localize ADI1 mRNA expression in the human prostate.
Figure 3A shows an expression of ADI1 mRNA in epithelial
cells, with little or no expression in stromal cells. This finding
is consistent with a previous observation that the epithelial
cells of the rat prostate specifically express ADI1 as do
LNCaP cells, which are of epithelial origin [7].
ADI1 Is Downregulated in High-Grade Prostate Tumors
To determine whether human prostate cancer tissues
have altered ADI1 expression, we performed immunohisto-
chemistry with our polyclonal ADI1 antibodies on a tissue
array of prostate tumors. We have previously demonstrated
that the antibody, which is generated with a human ADI1
peptide and affinity purification, recognizes rat and human
ADI1 [7]. Figure 3B shows ADI1 staining in a representative
specimen containing both benign tissues and a Gleason
grade 3 tumor; tumor cells had less ADI1 protein than the
benign region. The ADI1 staining intensity in the prostate tis-
sue array was scored from 1 to 4 using the Grizzle method,
with 4 representing the highest intensity of staining [21]. Tu-
mors displayed an obvious downregulation of ADI1 protein
levels (Figure 3C), which is consistent with the downregula-
tion of ADI1 mRNA in prostate cancer cell lines [7].
Expression of ADI1 mRNA Is Regulated By Androgens
in LNCaP Cells
We first identified ADI1 as an androgen-responsive gene
in the rat ventral prostate [7,26]. To determine whether an-
drogen regulation of ADI1 also occurs in humans, we used
the androgen-sensitive human prostate cancer cell line
LNCaP [27]. LNCaP cells were treated with 1 nM of the syn-
thetic androgen Mib, and ADI1 expression was determined
by Northern blot analysis. Mib induces ADI1 mRNA, with an
increase in expression occurring within 24 hours of treatment
(Figure 4A). Western blot analysis demonstrated that the
increase in ADI1 mRNA is accompanied by an increase in
Figure 1. Genomic structure of the human ADI1 gene. ADI1 is found in chromosome 2 at 2p25.3. The gene is encoded by four exons and has three introns. ADI1
protein consists of 179 amino acids, with the residues involved in binding Fe2+ or Ni 2+, His88, His90, His133, Asp92 (Fe2+), and Glu94 (Ni2+) [9,16] shown.
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protein levels (Figure 4B). To determine whether ADI1 is a
primary androgen-responsive gene, we tested whether ADI1
mRNA induction by Mib requires new protein synthesis. Fig-
ure 4C shows that the protein inhibitor CHX did not affect
ADI1mRNA upregulation byMib in LNCaP cells, indicating that
androgens directly induce ADI1.
Enzymatic Activity Assay of Recombinant ADI1 Protein
ARD catalyzes the reaction between O2 and the aci-
reductone intermediate in the methionine salvage pathway.
To determine whether human ADI1 protein has aci-reduc-
tone dioxygenase (ARD) activity, we expressed human ADI1
in E. coli BL21 bacterial cells (Figure 5A). Aci-reductone was
produced in vitro under anaerobic conditions [23], and the
amount obtained was monitored spectroscopically. ARD
activity was assayed by combining aci-reductone with bac-
terial lysates under aerobic conditions and by measuring the
decay of aci-reductone at 305 nm. Lysates containing wild-
type ADI1 exhibited at least a five-fold increase in ARD ac-
tivity over endogenous activity (Table 1).
The ADI1 Metal-Binding Site Is Not Required for Apoptosis
and Growth Inhibition
ARD enzymes require a metal cofactor for enzymatic
activity [8,9,15]. Therefore, we tested the effect of mutating
the amino acids likely required for metal binding on ADI1
function in prostate cancer cells. We have previously dem-
onstrated that rat Adi1 induced prostate cancer cell death
[7], so we measured apoptosis in PC3 cells expressing
mutated ADI1. Seven ADI1 point mutants were constructed
by substituting alanine for residues expected to ligate the
metal ion cofactor in the active site: H1 (His88Ala), H2
(His90Ala), H3 (His133Ala), E1 (Glu94Ala), H1H3 (His88Ala
and His133Ala), H1H2E1 (His88Ala + His90Ala + Glu94Ala),
and H1H2H3E1 (His88Ala + His90Ala + His133Ala +
Glu94Ala). In the bacterial ortholog of ADI1, mutating the
corresponding residues to alanine eliminates both the ability
of ADI1 to bind metal and its function as an ARD enzyme
[13]. Single mutants of ADI1 were strongly expressed (Fig-
ure 5B), yet the specific activity of mutant lysates is less
than that of lysates derived from BL21(DE3) cells containing
an empty pET28 vector (Table 1). This observation suggests
that overexpression of ADI1 protein suppresses endogenous
bacterial enzymes: thus, mutations decrease the enzymatic
activity of ADI1 by at least a factor of 50. Although double
and triple mutants are poorly expressed, it is reasonable to
expect that these variants would also be inactive.
To evaluate the subcellular location of the mutants, each
was fused to GFP at its N-terminus. Fluorescent microscopy
of PC3 cells 24 hours posttransfection revealed that wild-
type ADI1 and the different mutants exhibited a similar
Figure 2. Northern blot analysis of ADI1 expression in indicated human tis-
sues. Northern blot filters contain polyA+ RNA from indicated tissues and were
purchased fromClontech. -Actin served as the control for RNA loading levels.
Figure 3. (A) In situ hybridization analysis of ADI1 mRNA in BPH tissue. Both
antisense (right panel) and sense (left panel) ADI1 RNA probes were labeled
with DIG and visualized with alkaline phosphatase–conjugated anti-DIG anti-
body. Epithelial (E) and stromal (S) cells are indicated by arrows. (B) Immu-
nohistochemistry staining for ADI1 in the human prostate. Pictures show a
representative benign prostate section and a Gleason 3 prostate tumor sec-
tion in a single specimen stained with anti-ADI1 antibodies. Arrows indicate
either benign or cancerous prostatic epithelial cells. (C) Quantitative analysis
of the prostate cancer tissue array for ADI1. Staining intensity was adapted
from Grizzle et al. [21], and Gleason scores were adapted from an indepen-
dent pathologist (Northwestern Pathology Core Facilities). Numbers in paren-
theses indicate the number of samples.
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localization, with fluorescence seen primarily in the perinu-
clear region in a punctate pattern (Figure 6A). Moreover, both
wild-type and mutant ADI1 induced apoptosis, as indicated
by altered Hoechst staining (Figure 6A). Quantitation of ap-
optosis in transfected cells, based on Hoechst staining,
membrane blebbing, and cell detachment 48 hours post-
transfection, demonstrated that mutant and wild-type pro-
teins induced similar levels of cell death (Figure 6B). This
suggests that metal binding and probably ARD enzymatic
activity are not required for ADI1-induced apoptosis. More-
over, the use of transient transfection to introduce ADI1 ex-
pression was only 10% efficient, with varying levels of
proteins per cell (data not shown); yet, approximately 90%
of transfected cells died. This argues that apoptosis is in-
duced at various levels of ADI1 and that very little protein
is required.
We also performed a colony formation assay using trans-
fected LNCaP cells. After selection, only about 15% of the
colonies transfected with the GFP-tagged wild-type ADI1 ex-
pression vector were GFP-positive, whereas approximately
80% of the colonies transfected with GFP alone were GFP-
positive (Figure 7), indicating that ADI1 suppresses LNCaP
colony formation. Interestingly, mutations in the predicted
metal-binding site of ADI1 did not affect its ability to inhibit
colony formation. Decreased colony formation can be con-
sistent with increased apoptosis; thus, this result may sup-
port our previous observation that ADI1-induced apoptosis
does not require metal binding.
Discussion
ADI1 belongs to the family of ARD/ARDV proteins that par-
ticipate in the methionine salvage pathway [10–12]. These
evolutionarily conserved enzymes can be found in organ-
isms ranging from bacteria to humans. We have recently re-
ported the induction of apoptosis by rat Adi1 overexpression
in transfected prostate cancer cell lines [7]. However, both
the expression and the function of human ADI1 in the pros-
tate remain unknown. In this article, we report the down-
regulation of ADI1 in human prostate cancer specimens and
the ability of human ADI1 to induce apoptosis and to sup-
press colony formation in prostate cancer cells.
Similar to what we have observed in the rat prostate, an-
drogens regulated human ADI1 expression in LNCaP pros-
tate cancer cells. Thus, androgen regulation of ADI1 in the
prostate is conserved between rats and humans. The protein
synthesis inhibitor CHX did not inhibit androgen induction of
Figure 4. (A) Northern blot analysis of the androgen regulation of ADI1
expression in LNCaP cells. LNCaP cells were grown in a medium containing
10% cFBS to remove all androgens. The total RNA harvested from LNCaP
cells were treated with androgens (1 nM Mib) for indicated times. ADI1mRNA
is indicated by an arrow. (B) Western blot analysis of the androgen regulation
of ADI1 protein expression. LNCaP cells were grown in RPMI 1640 medium
containing 10% cFBS for 2 days to remove all androgens. Then cells were
treated with 1 nM Mib, and cell lysates were collected at indicated time points.
ADI1 protein is indicated by the arrow at 20 kDa, which is the predicted size.
-Actin served as the control for equal protein loading. (C) Northern blot anal-
ysis of the androgen regulation of ADI1 mRNA in the presence of CHX. Total
RNA was harvested from androgen-deprived LNCaP cells and LNCaP cells
treated with 1 nM Mib, 10 g/ml CHX, or both. ADI1 mRNA is indicated by
the arrow. The loading and the quality of total RNA in each lane were evaluated
by staining the nylon membrane after transfer with methylene blue [39].
Figure 5. (A) Expression of recombinant human ADI1 protein. The IPTG-
induced expression of ADI1 protein in BL21 transformed with pET-ADI1 was
detected by Western blot analysis using anti-ADI1 antibodies. BL21 trans-
formed with pET28a was used as a control in parallel. The total E. coli lysates
were visualized by Coomassie blue staining. Approximate molecular masses
are indicated on the left (kDa). ADI1 protein has an expected molecular mass
of 21,498 Da. (B) Coomassie-stained 15% SDS-PAGE of cell extracts ex-
pressing an empty vector or a vector containing ADI1. Empty vector and wild-
type ADI1 are pET28a; mutant ADI1 constructs are expressed from pET23a.
Approximate molecular masses are indicated on the left.
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ADI1, indicating that ADI1 is a primary androgen-responsive
gene. The ability of androgen to induce the expression of a
growth-inhibitory gene is not surprising. Although androgen in-
duces growth in a regressed prostate, it does not in a mature
prostate. Instead, androgen maintains the homeostasis of a
mature prostate and, in this context, induces the expression of
growth-inhibitory genes. This balance becomes disrupted in
prostate cancer. Given the importance of androgens in pros-
tate cancer, this observation supports the possibility that ADI1
plays a role in this disease.
The downregulation of ADI1 protein expression in human
prostate cancer specimens argues that ADI1 potentially in-
hibits the growth that occurs during prostate cancer progres-
sion. This finding substantiates our previous observation that
prostate cancer cell lines have downregulated ADI1 expres-
sion. The human ADI1 gene localizes to chromosome 2 at
the 2p25.3 locus, a region that contains a potential novel
tumor suppressor and is often lost in high-grade prostate tu-
mors [28]. Introduction of this chromosomal region into the
highly metastatic rat prostate cancer cell line AT6.1 signifi-
cantly inhibited the metastasis of this tumor cell line in se-
vere combined immunodeficient mice [28]. Because ADI1 is
inhibitory in prostate cancer, ADI1 could be one of the genes
responsible for metastasis suppression in this region.
Stable transfection of LNCaP cells with GFP-ADI1 signif-
icantly inhibited the number of colonies formed compared
with transfection with GFP alone. This finding is consistent
with our previous observation that ADI1 is proapoptotic. In
combination with downregulation of ADI1 in human prostate
cancer specimens, this observation strongly suggests an
inhibitory role for ADI1 in prostate cancer progression.
ADI1 shares homology with ARD enzymes, prompting the
question of whether ADI1 possesses ARD activity. Northern
blot analysis of ADI1 expression in different human tissues
shows that the highest levels of ADI1 expression occur in
the liver, kidney, and prostate. The liver is a major site for
methionine salvage in the body [12], supporting the pos-
sibility that ADI1 may function as an ARD enzyme. The
prostate has one of the highest polyamine concentrations
of any tissue [29,30]. The methionine salvage pathway re-
cycles methylthioadenosine, an inhibitory byproduct of poly-
amine biosynthesis [31–34]; thus, a high-level expression of
ADI1 in the prostate may facilitate the necessary polyamine
Table 1. Specific Activities of Soluble Cell Extracts Containing Wild-Type
and Mutant ADI1 Constructs.
Amount of Protein
Assayed (mg)
kobs (s
1) Specific Activity
(mmol/min per mg)
No lysate control NA 0.005 NA
Empty pET-28a 4 0.01 8
Wild-type ADI1 11 0.14 39
H1A 13 0.02 0.5
H2A 16 0.03 0.7
H3A 14 0.02 0.5
E1A 16 0.02 0.4
H1AH3A 18 0.01 ND
H1AH2AE1A 12 0.02 ND
H1AH2AE1AH3A 9 0.02 ND
ADI1 activity was determined by monitoring the decrease in the absorbance
of aci-reductone (kmax = 305 nm) for 3 minutes. The protein content of cell
extracts was determined by Bradford assay.
H1A, H88A; H2A, H90A; H3A, H133A; E1A, E94A; ND, not determined; NA,
not applicable.
Specific activity is calculated by subtracting the background rate from kobs
and dividing by the amount of protein assayed.
Figure 6. (A) Subcellular localization of GFP-tagged wild-type and mutant
ADI1 constructs in transiently transfected PC3 cells. Green fluorescent
microscopy 24 hours posttransfection shows that ADI1 wild-type and mutant
proteins have a similar subcellular localization. Hoechst staining revealed
fragmented nuclei in cells transfected with GFP-tagged ADI1 or ADI1 mu-
tants, but not in cells transfected with GFP only. (B) Percentage of dead PC3
cells 48 hours after transfection with GFP-ADI1 constructs. Dead GFP-
positive cells were scored by fragmented nuclei and membrane blebbing.
ADI1 mutant proteins had a similar ability to induce apoptosis in PC3 cells.
The results represent the mean of three independent experiments, and error
bars represent standard errors. *P < .001.
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production. A potential role for ADI1 in the methionine sal-
vage pathway is further supported by our finding that hu-
man ADI1 possesses enzymatic activity as an ARD in an
in vitro assay.
Our experiments argue that the proapoptotic activity of
ADI1 appears to be independent of its ARD enzymatic ac-
tivity. The best-characterized role for the ARD/ARDV family is
its ability to act as an ARD, a function that requires metal
binding [8,9,15]. There are four conserved amino acid resi-
dues (His88, His90, His133, and Glu94) that are critical for
metal binding based on the structural analysis of these pro-
teins [9,16]. Substitution of one, two, three, or four of these
conserved amino acid residues did not affect the ability of
ADI1 to induce apoptosis or to suppress the colony formation
of prostate cancer cells, suggesting that ADI1 may mediate
apoptosis through another mechanism. Indeed, ADI1 has
been reported to have additional functions. ADI1 can bind
to and inhibit the activity of MT1-MMP [17]. The alternative
splice variant of ADI1, the protein Sip-L, consists of ADI1
amino acids 64 to 179 and can support hepatitis C virus rep-
lication in a nonpermissive cell line [35]. The yeast homo-
logue of ADI1, YMR009w, encodes a potential binding protein
of a splicing factor SNP-1, according to the comprehensive
yeast protein–protein interaction database [36]. Future stud-
ies will be required to determine whether ADI1 induction of
apoptosis in prostate cancer involves one of the above re-
ported functions for ADI1 or a novel mechanism.
Microscopy revealed that GFP-ADI1 is found in a punc-
tuate pattern that coincides with membrane ruffling and is
near the perinuclear space. A similar punctuate subcellular
localization was seen with V5 epitope-tagged Sip-L [35]. Hy-
drophobicity plots of ADI1 indicate that it is a very polar mol-
ecule (data not shown). Thus, we speculate that ADI1 may
interact with polar head groups of the inner leaflet of the
plasma membrane. Others have shown that ADI1 binds the
cytoplasmic tail of MT1-MMP, inhibiting its activity [17]. This
provides another explanation for the subcellular localization
of ADI1. The colocalization of ADI1 and MTI-MMP would fur-
ther suggest a role for ADI1 in prostate cancer, as MT1-MMP
expression is upregulated in prostate tumors [37] and plays
a role in enhancing migration through the cleavage of base-
ment membrane proteins [38]. Our observation that ADI1 pro-
tein tagged with GFP at the C-terminus resulted in the same
subcellular localization as protein tagged at the N-terminus
(data not shown) indicates that GFP tag likely did not interfere.
In summary, our studies demonstrate the ability of human
ADI1, whose expression is androgen-mediated, to induce
apoptosis and to inhibit colony formation. Furthermore, we
observed the downregulation of ADI1 in human prostate can-
cer specimens. Together, these observations support an in-
hibitory role for ADI1 in prostate cancer progression. Although
ADI1 has ARD activity, the suppressive activity of ADI1 ap-
pears to be independent of this. Thus, a better understanding
of prostate cancer progression will require further investigation
of ADI1 activity in prostate cells.
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